


FORM PT0-1390 (REV 10-95)		U S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTORNEY'S DOCKET NUMBER	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. §371		SCH 1869	
INTERNATIONAL APPLICATION NO		U.S. APPLICATION NO. (if known, see 37 CFR §1.5) 10/088866	
PCT/EP00/08121		INTERNATIONAL FILING DATE 19 AUGUST 2000	
PRIORITY DATE CLAIMED 24 SEPTEMBER 1999			
TITLE OF INVENTION ANTIBODY DYE CONJUGATES FOR BINDING TO TARGET STRUCTURES OF ANGIOGENESIS IN ORDER TO INTRAOPERATIVELY DEPICT TUMOR PERIPHERIES			
APPLICANT(S) FOR DO/EO/US SCHIRNER, Michael, et al			
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. §371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. §371. 3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. §371(c)(2)) <ul style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau) b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. §371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3)) <ul style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. §371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)). <p>Items 11. to 16. below concern document(s) or information included:</p> <ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. §§1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. §§3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <ul style="list-style-type: none"> <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input type="checkbox"/> Other items or information: 			

U.S. APPLICATION NO. (If known, see 37 CFR § 1.492(e)) 10708866	INTERNATIONAL APPLICATION NO PCT/EP00/08121	ATTORNEY'S DOCKET NUMBER SCH 1869
17. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS PTO USE ONLY
BASIC NATIONAL FEE (37 CFR §1.492 (a) (1) - (5)):		
Search Report has been prepared by the EPO or JPO.....		\$890.00
International preliminary examination fee paid to USPTO (37 CFR §1.482).....		\$710.00
No international preliminary examination fee paid to USPTO (37 CFR §1.482) but international search fee paid to USPTO (37 CFR §1.445(a)(2)).....		\$740.00
Neither international preliminary examination fee (37 CFR §1.482) nor international search fee (37 CFR §1.445(a)(2)) paid to USPTO		\$1040.00
International preliminary examination fee paid to USPTO (37 CFR §1.482) and all claims satisfied provisions of PCT Article 33(2)-(4).		\$100.00
ENTER APPROPRIATE BASIC FEE AMOUNT =		
\$890.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 C F R. §1.492(c)).		
<input type="checkbox"/> 20 <input type="checkbox"/> 30		
CLAIMS	NUMBER FILED	NUMBER EXTRA
Total claims	14 - 20 =	0
Independent claims	1 - 3 =	0
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ \$ 280.00
TOTAL OF ABOVE CALCULATIONS =		
\$890.00		
Reduction of 1/2 for filing by small entity, if applicable. A Verified Small Entity Statement must also be		
SUBTOTAL =		
\$890.00		
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 C.F.R. §1.492(f)).		
<input type="checkbox"/> 20 <input type="checkbox"/> 30		
TOTAL NATIONAL FEE =		
\$890.00		
Fee for recording the enclosed assignment (37 C F R. §1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. §§3.28, 3.31). \$40.00 per property.		
TOTAL FEES ENCLOSED =		
\$890.00		
		Amount to be refunded:
		charged.
<p>a. <input checked="" type="checkbox"/> A check in the amount of <u>\$890.00</u> to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No <u>13-3402</u> in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>13-3402</u>. A duplicate copy of this sheet is enclosed.</p>		
<p>NOTE: Where an appropriate time limit under 37 C.F.R. §§1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. §1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>		
SEND ALL CORRESPONDENCE TO Customer Number 23,599		
 23599 <small>PATENT TRADEMARK OFFICE</small>		
 SIGNATURE Anthony J. Zelano NAME 27,969 REGISTRATION NUMBER		
Filed: 22 MARCH 2002		
AJZ:kmo		

10/088866

JC10 Rec'd PCT/PTO 22 MAR 2002

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. : PCT/EP00/08121
International Filing Date : 19 AUGUST 2000
Priority Date(s) Claimed : 24 SEPTEMBER 1999
Applicant(s) (DO/EO/US) : SCHIRNER, Michael, et al.

Title: ANTIBODY DYE CONJUGATES FOR BINDING TO TARGET STRUCTURES OF ANGIOGENESIS IN ORDER TO INTRAOPERATIVELY DEPICT TUMOR PERIPHERIES

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

SIR:

Prior to calculating the national fee, and prior to examination in the National Phase of the above-identified International application, please amend as follows:

IN THE CLAIMS:

3. (Amended) Antibody-dye conjugates according to claim 1, wherein the dye is a cyanine dye, a merocyanine dye, an oxonol dye, a styryl dye or a squarilium dye.
4. (Amended) Antibody-dye conjugates according to claim 1, wherein the dye is a cyanine dye such as carbocyanine, dicarbocyanine or tricarbocyanine.

5. (Amended) Antibody-dye conjugates according to claim 1, wherein dye - (F)_n of general formula I is a cyanine dye of general formula II in which D stand for a radical III or IV whereby the position labeled with a star means the interface site with radical B, and B can stand for group V, VI, VII, VIII or IX in which R¹ and R² mean C₁-C₄ sulfoalkyl, a saturated or unsaturated, branched or linear C₁-C₅₀ alkyl chain, which optionally can be substituted with up to 15 oxygen atoms, and/or with up to 3 carbonyl groups, and/or with up to 5 hydroxy groups, R³ stands for group -COOE¹, -CONE¹E², -NHCOE¹, -NHCONHE¹, -NE¹E², -OE¹, -OSO₃E¹, -SO₃E¹, -SO₂NHE¹ or -E¹, whereby E¹ and E², independently of one another, stand for a hydrogen atom, C₁-C₄ sulfoalkyl, saturated or unsaturated, branched or straight-chain C₁-C₅₀ alkyl, which optionally is interrupted with up to 15 oxygen atoms, and/or with up to 3 carbonyl groups, and/or can be substituted with up to 5 hydroxy groups, R⁴ stands for a hydrogen atom or a fluorine, chlorine, bromine or iodine atom, b stands for 2 or 3, x stands for oxygen, sulfur or the group =C(CH₃)₂ or - (CH=CH) -, and L stands for a direct bond or linker, which is a straight-chain or branched carbon chain with up to 20 carbon atoms, which can be substituted with one or more -OH, -COOH, or SO₃ groups and/or optionally can be interrupted in one or more places by an -O-, -S-, -CO-, -CS-, -CONH-, -NHCO-, -NHCSNH-, -SO₂-, PO₄⁻ or an -NH group or an aryl ring.

6. (Amended) Antibody-dye conjugates according to claim 1, wherein antibodies L19 and E8 are used as antibodies.

7. (Amended) Antibody-dye conjugates according to claim 1, wherein the dye in the visible spectral range of the light induces an optical signal.

8. (Amended) Antibody-dye conjugates according to claim 1, wherein the dye induces a fluorescence signal only with use of a defined wavelength range of the visible or near-infrared light.

9. (Amended) Pharmaceutical agent comprising one or more antibody-dye conjugates according to claim 1 for intraoperative visualization of the edge areas of a focus of disease.

11. (Amended) Use of the antibody-dye conjugates and agents according to claim 1 for intraoperative visualization of foci of disease.

12. (Amended) Use of antibody-dye conjugates according to claim 1 for intraoperative visualization of the edge areas of a focus of disease.

13. (Amended) Use of antibody-dye conjugates according to claim 1 for microscopic and macroscopic intraoperative visualization of the edge areas of a focus of disease.


14. (Amended) Use of the antibody-dye conjugates according to claim 1 for the production of an agent for surgical treatment of angiogenesis-dependent diseases, such as malignant tumors and metastases thereof, benign tumors, precancerous tissue changes, endometriosis, hemangiomas and ectopic pregnancies.

REMARKS

The purpose of this Preliminary Amendment is to eliminate multiple dependent claims in order to avoid the additional fee. Applicants reserve the right to reintroduce claims to canceled combined subject matter.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned "**Version With Markings to Show Changes Made**".

Respectfully submitted,



Anthony J. Zelano 4/22/004

Anthony J. Zelano, Reg. No. 27,969
Attorney for Applicants
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Boulevard, Suite 1400
Arlington, VA 22201
Direct Dial: 703-812-5311
Facsimile: 703-243-6410
Email: zelano@mwbz.com

AJZ:kmo

Filed: 22 March 2002

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claims 3 - 9 and 11 - 14 were amended as follows:

3. (Amended) Antibody-dye conjugates according to claims 1 and 2, wherein the dye is a cyanine dye, a merocyanine dye, an oxonol dye, a styryl dye or a squarilium dye.

4. (Amended) Antibody-dye conjugates according to claims 1 to 3, wherein the dye is a cyanine dye such as carbocyanine, dicarbocyanine or tricarbocyanine.

5. (Amended) Antibody-dye conjugates according to claims 1 to 4, wherein dye - (F)_n of general formula I is a cyanine dye of general formula II in which D stand for a radical III or IV whereby the position labeled with a star means the interface site with radical B, and B can stand for group V, VI, VII, VIII or IX in which R¹ and R² mean C₁-C₄ sulfoalkyl, a saturated or unsaturated, branched or linear C₁-C₅₀ alkyl chain, which optionally can be substituted with up to 15 oxygen atoms, and/or with up to 3 carbonyl groups, and/or with up to 5 hydroxy groups, R³ stands for group -COOE¹, -CONE¹E², -NHCOE¹, -NHCONHE¹, -NE¹E², -OE¹, -OSO₃E¹, -SO₃E¹, -SO₂NHE¹ or -E¹, whereby E¹ and E², independently of one another, stand for a hydrogen atom, C₁-C₄ sulfoalkyl, saturated or unsaturated, branched or straight-chain C₁-C₅₀ alkyl, which optionally is interrupted with up to 15 oxygen atoms, and/or with up to 3 carbonyl groups, and/or can be substituted with up to 5 hydroxy groups, R⁴ stands for a hydrogen atom or a fluorine, chlorine, bromine or iodine atom, b stands for 2 or 3, x stands for oxygen, sulfur or the group =C(CH₃)₂ or - (CH=CH) -, and L stands for a direct bond or linker, which is a straight-chain or branched carbon chain with up to 20 carbon atoms, which can be substituted with one or more -OH, -COOH, or SO₃ groups and/or optionally can be interrupted in one or more places by an -O-, -S-, -CO-, -CS-, -CONH-, -NHCO-, -NHCSNH-, -SO₂-, PO₄⁻ or an -NH group or an aryl ring.

6. (Amended) Antibody-dye conjugates according to claims 1-to-5, wherein antibodies L19 and E8 are used as antibodies.

7. (Amended) Antibody-dye conjugates according to claims 1-to-6, wherein the dye in the visible spectral range of the light induces an optical signal.

8. (Amended) Antibody-dye conjugates according to claims 1-to-6, wherein the dye induces a fluorescence signal only with use of a defined wavelength range of the visible or near-infrared light.

9. (Amended) Pharmaceutical agent comprising one or more antibody-dye conjugates according to claims 1-to-8 for intraoperative visualization of the edge areas of a focus of disease.

11. (Amended) Use of the antibody-dye conjugates and agents according to claim 1 to-10 for intraoperative visualization of foci of disease.

12. (Amended) Use of antibody-dye conjugates according to claims 1-to-10 for intraoperative visualization of the edge areas of a focus of disease.

13. (Amended) Use of antibody-dye conjugates according to claims 1-to-10 for microscopic and macroscopic intraoperative visualization of the edge areas of a focus of disease.

14. (Amended) Use of the antibody-dye conjugates according to claims 1-to-8 for the production of an agent for surgical treatment of angiogenesis-dependent diseases, such as malignant tumors and metastases thereof, benign tumors, precancerous tissue changes, endometriosis, hemangiomas and ectopic pregnancies.

10/088866

JC10 Rec'd PCT/PTO 22 MAR 2002

Antibody-Dye Conjugates for Angiogenesis Target Structures for
Intraoperative Tumor Edge Visualization

This invention relates to antibody-dye conjugates that are suitable to bind to structures of newly formed vessels and their use for intraoperative visualization of pathological angiogenesis.

In the adult organism, no new vessel formation takes place, with few exceptions (e.g., the cycle of women of child-bearing age). The new vessel formation can be observed, however, in many diseases. The process of the new vessel formation that takes place here is referred to as angiogenesis and takes place as a response to certain signals.

Angiogenesis is a process that preferably takes place in the edge area of a focus of disease. From the center of the focus of disease, factors are released that diffuse to the edge area of the focus of disease. These factors are also referred to as angiogenesis stimulators. If these angiogenesis stimulators reach the healthy tissue in the edge area of a focus of disease, the vessels previously not integrated in the focus of disease are stimulated to form new vessel buds. The vessels that extend from these vessel buds form a new capillary vascular network in the edge area of the focus of disease. By this process, a suitable nutrient supply for the focus of disease can always be ensured. It has proven especially important that the growth of tumors and their metastases depends on the ability to induce angiogenesis.

Surgical therapy is now a standard measure for treating localized foci of disease. It has obtained great importance in the case of tumor treatment. It has turned out, however, that despite improved surgical techniques, the number of local recurrences is considerable, since the anatomical conditions in the human organism only rarely allow a large-scale removal of the focus of disease. In many organs (e.g., in the brain), large-scale removal must be eliminated to obtain healthy tissue. The risk of damaging healthy organs increases with the degree of radicalness of surgical intervention.

Histological studies of the edge area of the tumor after the completion of surgical tumor removal have shown, however, that a considerable number of tumors cannot be removed completely, and tumor radicals remain in the body. Additional tumor growth and also tumor metastasizing can spring from these tumor radicals. A process that exactly indicates the limits of a disease process with respect to healthy tissue during surgical treatment would allow the focus of disease to be removed completely and to leave the healthy tissue unaffected to a large extent.

Dyes for the visualization of foci of disease are already known (Poon, W. S. et al., J. Neurosurgery (1992) 76: 679-686, Haglund, M. M. et al., Neurosurgery (1996) 38: 308-317). They are preferably removed directly from tumor cells or accumulate unspecifically in the extracellular space of tumors. Since the mechanism can be detected in the concentration even in healthy tissue, the specificity and sensitivity of the substances that are used is low.

Compounds that can be used for intraoperative delineation of the foci of disease by selective visualization of the edge area of a focus of disease are not known to date.

The angiogenesis preferably takes place in the edge area of foci of disease. By visualization of the angiogenesis, the limit in healthy tissue can be visualized. Antibodies for detecting angiogenesis in the focus of disease are already known and are used for visualizing newly formed vessels in the histological tissue section, for detecting various proteins in the focus of disease or as carrier molecules for therapeutic substances.

Antibodies in combination with dyes, so-called antibody-dye conjugates, that can be used for intraoperative delineation of the focus of disease by selective visualization of the edge area of a focus of disease are not known, however.

The object of this invention is therefore to prepare antibody-dye conjugates for the intraoperative tumor edge visualization. The antibodies of the antibody-dye conjugates according to the invention are directed against structures that are specifically for the process of angiogenesis. The antibody-dye conjugates according to the invention comprise dyes that make possible an optical visualization by their concentration.

Since the angiogenesis is made most strongly in the edge area of a focus of disease, it results here in the maximum optical signal.

The antibody-dye conjugates according to the invention are thus suitable to visualize the limits of a focus of disease, the so-called edge area, for healthy tissue by intraoperative,

optical diagnosis. It is consequently made possible to remove the focus of disease completely in leaving healthy tissue largely unaffected.

Antibodies are known that are directed against molecules that are strongly expressed in angiogenetically active tissue and are expressed only to a very small level in the adjoining tissue (WO 96/01653).

Antibodies that are directed against the receptors for vascular growth factors, receptors in endothelial cells to which inflammation mediators bind, receptors in endothelial cells to which matrix molecules bind, and matrix proteins that are expressed specifically in the new vessel formation (Brekken et al., Cancer Res. (1998) 58: 1952-9 and Schold, S. C. Jr. et al., Invest. Radiol. (1993) 28: 488-96) are of special interest in antibody-dye conjugates.

Preferred are antibodies or antibody fragments that are directed against the matrix protein EDB-fibronectin. EDB-fibronectin (EDBFN), also known as oncofetal fibronectin, is a splice variant of the fibronectin, which specifically forms newly formed vessels in the process of angiogenesis. The special advantage of antibodies against the EDB-fibronectin consists in that it does not result in any new formation of EDB-fibronectin in healthy tissue by intraoperative injury in the removal of the focus of disease. In this connection, the specificity is preserved during the surgical intervention. Antibodies against growth factor receptors or inflammation mediators in the endothelial cells, which are also expressed specifically in the

tumor edge area, can be newly formed, however, during the surgical intervention even in healthy tissue near the focus of disease.

Especially preferred in the inventive antibody-dye conjugate are antibody L19 and E8 against the EDB-fibronectin (Viti, F., et al., Cancer Res. (1999) 59: 347-352).

Such antibody-dye conjugates are also the subject matter of this invention.

The known antibodies are conjugated with dyes, whose concentration in the tissue can be optically detected and makes possible the intraoperative delineation of the edge area of a focus of disease.

The advantage of the antibody-dye conjugates according to the invention now consists in the fact that the latter can be used for a selective fluorescence staining of tissues in a neoangiogenetic stage. The fluorescence staining is tumor-specific and yields a fluorescence signal that can be detected in a high signal-to-background ratio.

Antibody-dye conjugates for fluorescence imaging are also known for purposes of percutaneous, non-invasive tumor visualization (Neri, D. et al., Nature Biotechnology (1997) 15: 1271-1275).

Not known, however, are antibody-dye conjugates, which preferably accumulate in the edge area of a focus of disease.

Protein-dye conjugates for intraoperative tumor visualization are also known.

The disadvantage to these conjugates is that especially hypoxic and metabolically undernourished tumor cells take up the conjugates. Since the tissue in the edge area of tumors is well vascularized, however, and in this connection the cells are supplied adequately with oxygen and nutrients, for this very reason adequate accumulation of the known protein-dye conjugates is not possible.

The antibody-dye conjugates according to the invention are largely independent of the metabolic state of the focus of disease, however.

Although the optical detection of the limits of a focus of disease can be carried out in different ways, in general the detection of the dye-specific fluorescence radiation induced by corresponding stimulation light is preferred. Depending on the emission wavelength, in this case the fluorescence can be visually detected directly macroscopically or microscopically and optionally simultaneously recorded digitally by imaging detection systems and visualized on a display.

Fluorescence radiation of the spectral range of 400 to 650 nm is visually detectable. Especially preferred is a wavelength of 450 to 600 nm. The special advantage of the use of the visible range of light consists in the fact that the detection of fluorescence by low technical expense is possible. Stimulation light, which is produced by suitable lasers or laser diodes, is coupled to a fiber optic light guide and is brought in by the latter to the area to be diagnosed. The implementation of the intraoperative tumor edge detection is carried out by large-scale

radiation of the area. The reflected stimulation light is blocked by a filter (e.g., a pair of filtering glasses that are worn by the person making the study), and only the dye-specific fluorescence is observed (macroscopic observation). As an alternative, the detection of the fluorescence can be carried out by an operating microscope (microscopic observation). By the small penetration depth of VIS light in the tissue (a few millimeters), new vascular formations located on the surface can be detected in this way.

Another advantage of the spectral range of visible light exists in the small penetration depth in the tissue and emission from the tissue. The detectable signal consequently is not distorted by signals from deeper portions of tissue and can be assigned specifically to the tissue structures that are visible on the surface.

The subjects of this invention are thus also antibody-dye conjugates, whose dyes induce an optical signal in the visible spectral range of the light.

The use of antibody-dye conjugates with dyes that absorb in the spectral range of near-infrared light (NIR; 600-900 nm) makes possible, however, the detection of new vascular formation in deeper tissue layers (up to 1 cm), since NIR light is absorbed more weakly from tissue and therefore has a larger tissue penetration depth. The observation of fluorescence is visually impossible and can be carried out by CCD-cameras (charge-coupled device camera), which are placed over the tissue area of interest. Both macroscopic and microscopic detection are

possible. The advantage of the use of dyes in the antibody-dye conjugates, which absorb and fluoresce in the NIR-spectral range, then is at work if an evaluation of masked areas (e.g., by blood) is necessary.

From the photophysical standpoint, those dyes that have an absorption maximum within the spectral range of 400 to 800 nm and at least one fluorescence maximum within 500 to 900 nm are suitable for antibody-dye conjugates.

The subjects of this invention are also antibody-dye conjugates that are characterized in that the dye induces a fluorescence signal only with use of a defined wavelength range of the visible or near-infrared light.

Antibody-dye conjugates that comprise dyes with visually detectable fluorescence are, for example, those from the following classes:

fluorescein, fluorescein-isothiocyanate, carboxyfluorescein or calcein,

tetrabromofluoresceins or eosins, tetraiodofluoresceins or erythrosins,

difluorofluorescein, such as, e.g., Oregon GreenTM 488, Oregon GreenTM 500 or Oregon GreenTM 514, carboxyrhodol (Rhodol GreenTM) -dyes (US 5,227,487; US 5,442,045), carboxyrhodamine dyes (e.g., Rhodamine GreenTM dyes) (US 5,366,860),

4,4-difluoro-4-bora-3a,4a-diaza-indacene, such as, e.g., Bodipy FL, Bodipy 493/503 or Bodipy 530/550 and derivatives thereof (US 4,774,339, US 5,187,288, US 5,248,782, US 5,433,896 and US 5,451,663),

cyanine dyes, especially carbocyanines and merocyanines, coumarin dyes, such as, e.g., 7-amino-4-methylcoumarin, metal complexes of DTPA or tetraazamacrocyclene (cyclene, pyclene) with terbium or europium or tetrapyrrole dyes, especially porphyrins.

Antibody-dye conjugates that comprise near-infrared dyes are, for example, those from the following classes:

polymethine dyes, such as dicarbocyanine, tricarbocyanine, merocyanine and oxonol dyes (WO 96/17628),

rhodamine dyes,

phenoxyazine or phenothiazine dyes,

tetrapyrrole dyes, especially benzoporphyrins, chorines and phthalocyanines.

Preferred near-infrared dyes in the antibody-dye conjugates are the cyanine dyes with absorption maxima of between 700 and 800 nm, especially indodi- and indotricarbocyanines.

Generally preferred are dyes in the antibody-dye conjugates from the above-mentioned classes, which have one or more carboxyl groups, which are coupled to amino groups of antibodies or antibody fragments after chemical activation. Those derivatives that contain maleimido or bromoalkyl radicals are also preferred, so that a covalent coupling to the sulphydryl group of the amino acid cysteine is carried out.

In addition, dyes that have isothiocyanate groups, which also react with amino groups, are preferred.

Moreover, the dyes in the antibody-dye conjugates must have a high photostability and do not bleach out under irradiation

with light (photobleaching) to ensure a constant signal within the study period.

The subjects of this invention are thus antibody-dye conjugates that preferably accumulate in the edge area of the cell tissue of a focus of disease and thus make the edge area of the focus of disease optically detectable.

In particular subjects of this invention are antibody-dye conjugates of general formula I



in which

B stands for an antibody or an antibody fragment with high binding to ED-BFN,

F stands for a dye from the class of coumarins, fluoresceins, carboxyfluoresceins, difluorofluoresceins, tetrabromofluoresceins, tetraiodofluoresceins, rhodamines, carboxyrhodamines, carboxyrhodols, 4,4-difluoro-4-bora-3a,4a-diaza-indacenes, polymethine dyes or tetrapyrrole dyes, or the terbium or europium complexes with DTPA or cyclene and its derivatives, and


n stands for 1 to 5.

Especially preferred and thus also the subjects of this invention are antibody-dye conjugates, whose dye is a cyanine dye, a merocyanine dye, an oxonol dye, a styryl dye or a squarilium dye.

Especially preferred and thus also subjects of this invention are antibody-dye conjugates in which the dye portion is


a cyanine dye, especially a carbocyanine, dicarbocyanine or tricarbocyanine.

The invention thus relates in particular to those antibody-dye conjugates in which dye -(F)_n of general formula I is a cyanine dye of general formula II




in which

D stands for a radical III or IV



whereby the position labeled with a star means the interface site with radical B, and

B can stand for group V, VI, VII, VIII or IX



in which

R^1 and R^2 mean C_1 - C_4 sulfoalkyl, a saturated or unsaturated, branched or linear C_1 - C_{50} alkyl chain, which optionally can be substituted with up to 15 oxygen atoms, and/or with up to 3 carbonyl groups, and/or with up to 5 hydroxy groups,

R^3 stands for group $-COOE^1$, $-CONE^1E^2$, $-NHCOE^1$, $-NHCONHE^1$, $-NE^1E^2$, $-OE^1$, $-OSO_3E^1$, $-SO_3E^1$, $-SO_2NHE^1$ or $-E^1$, whereby E^1 and E^2 , independently of one another, stand for a hydrogen atom, C_1 - C_4 sulfoalkyl, saturated or unsaturated, branched or straight-chain C_1 - C_{50} alkyl, which optionally is interrupted with up to 15 oxygen atoms, and/or up to 3 carbonyl groups, and/or can be substituted with up to 5 hydroxy groups,

R^4 stands for a hydrogen atom or a fluorine, chlorine, bromine or iodine atom,

b stands for 2 or 3,

x stands for oxygen, sulfur or the group $=C(CH_3)_2$ or $-(CH=CH)-$, and

L stands for a direct bond or a linker, which is a straight-chain or branched carbon chain with up to 20 carbon atoms, which can be substituted with one or more $-OH$, $-COOH$, or SO_3 groups and/or optionally can be interrupted in one or more places by an $-O-$, $-S-$, $-CO-$, $-CS-$, $-CONH-$, $-NHCO-$, $-NHCSNH-$, $-SO_2-$, PO_4- or an $-NH$ group or an aryl ring.

The antibody-dye conjugates according to the invention can be used either alone or in a formulation as pharmaceutical agents.

To use the antibody-dye conjugates as pharmaceutical agents, the latter are brought into the form of a pharmaceutical preparation, which in addition to the antibody-dye conjugate contains pharmaceutical, organic or inorganic inert media that are suitable for enteral or parenteral administration, such as, for example, water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc. The pharmaceutical preparations can be present in solid form, for example as tablets, coated tablets, suppositories, capsules or in liquid form, for example as solutions, suspensions or emulsions. They optionally contain, moreover, adjuvants such as preservatives, stabilizers, wetting agents or emulsifiers, salts for altering the osmotic pressure or buffers.

For parenteral use, injection solutions or suspensions, especially aqueous solution of antibody-dye conjugates, are suitable.

As vehicle systems, surface-active adjuvants, such as salts of bile acids or animal or plant phospholipids, but also mixtures of them as well as liposomes or their components can also be used.

For oral use, especially tablets, coated tablets or capsules with talc and/or hydrocarbon vehicles or binders, such as, for example, lactose, corn or potato starch, are suitable. The

application can also be carried out in liquid form, such as, for example, as juice, to which optionally a sweetener is added.

The dosage of the antibody-dye conjugates can vary depending on the method of administration, age and weight of the patient, type and severity of the disease to be treated and similar factors. The applicable dose of the antibody-dye conjugates for detecting limit areas is 0.5-1000 mg, preferably 50-200 mg, whereby the dose can be given as a single dose to be administered once or divided into two or more daily doses.

The above-described formulations and forms for dispensing are also the subjects of this invention.

The invention thus also relates to pharmaceutical agents that comprise one or more antibody-dye conjugates for intraoperative visualization of the edge areas of a focus of disease, whereby the pharmaceutical agents are used either alone or in a mixture with suitable solvents, buffers and/or vehicles.

The antibody-dye conjugates according to the invention are used in the surgical treatment of angiogenesis-dependent diseases, such as malignant tumors and metastases thereof, benign tumors, precancerous tissue changes, endometriosis, hemangiomas and ectopic pregnancies.

Also a subject of this invention is the use of antibody-dye conjugates and agents for intraoperative visualization of foci of disease, especially for microscopic and macroscopic, intraoperative visualization of edge areas of a focus of disease, as well as the use of antibody-dye conjugates for the production of an agent for surgical treatments of angiogenesis-dependent

diseases, such as malignant tumors and metastases thereof, benign tumors, precancerous tissue changes, endometriosis, hemangiomas and ectopic pregnancies.

Production of Dyes

The production of dyes is carried out according to methods that are known in the literature. Suitable dyes for the production of antibody-dye conjugates are dyes of carboxyl groups or isothiocyanate groups for covalent coupling to amino groups of the antibody. Especially preferred in this case are cyanine dyes (Mujumdar, S. R. et al. (1996) 7: 356-362; Flanagan, J. H. et al. (1997) 8: 751-756 and Licha, K. et al. (1996) Proc SPIE Vol. 2927, 192-198).

The dyes with carboxyl groups are activated first by conversion into a reactive ester (e.g., N-hydroxysuccinimide ester) according to methods that are known in the art. Dyes with isothiocyanate groups can be used directly. The reactive derivatives are then brought to reaction in buffer solution or mixtures of organic solvent (e.g., dimethylformamide (DMF) or dimethyl sulfoxide (DMSO)) and buffer solution with the antibody. In this case, a 3- to 100-fold molar excess of dye is used. The unreacted portion is separated by ultrafiltration and/or chromatography after the reaction is completed.

The following dye is also produced by a similar method:

Production Example 1

Bis-1,1'-(4-sulfobutyl)indocarbocyanine-5-carboxylic acid-N-hydroxysuccinimide ester

The production of bis-1,1'-(4-sulfobutyl)indocarbocyanine-5-carboxylic acid is carried out starting from 1-(4-sulfobutyl)-2,3,3-trimethyl-3H-indolenine and 1-(4-sulfobutyl)-2,3,3-trimethyl-5-carboxy-3H-indolenine (Cytometry 10, 11-19, 1989, Talanta 39, 505-510, 1992) in a way similar to methods known in the literature.

For conversion into the N-hydroxysuccinimide ester, 0.1 mmol of dye (67 mg in 10 ml of DMF) is mixed in each case with 0.5 mmol of N-hydroxysuccinimide and dicyclohexylcarbodiimide (DCC) and stirred for 24 hours at room temperature. After 50 ml of ether is added, the precipitated solid is filtered off, dissolved again twice each in a little DDF and precipitated with ether and finally dried in a vacuum (yield 89%).

Production of the Antibody-Dye Conjugate

Production of a bis-1,1'-(4-sulfobutyl)indocarbocyanine conjugate with an L19-antibody

The antibody L19 (1 mg in 1 ml of sodium acetate buffer 50 mmol, pH 8.2)) is mixed with N-hydroxysuccinimide ester (75 μ mol of a solution of 4 mg/ml in DMSO) and stirred for 2 hours at room temperature. Purification is done using gel filtration on PD10-cartridges (Pharmacia) and concentration is done using Centricon-

10 tubes (Amicon) while obtaining a solution of about 1 mg/ml of antibody.

Absorption maximum: 555 nm

Fluorescence maximum: 582 nm.

The following example explains the biological usability of the antibody-dye conjugates according to the invention without limiting the latter to the sample application.

Sample Application 1

In vivo fluorescence imaging on tumor-carrying nude mice and microscopic ex-vivo examination of the tumor tissue

The imaging properties of the compounds according to the invention were examined *in vivo* after injection in tumor-carrying nude mice. For this purpose, 0.1 $\mu\text{mol}/\text{kg}$ to 2 $\mu\text{mol}/\text{kg}$ of the substance was administered intravenously, and the concentration in the tumor region is observed in a period of 0 to 48 hours. The fluorescence of the substances is induced by irradiation of the animals with light of corresponding wavelength, which is produced monochromatically with a laser (diode laser, solid-state laser) or is filtered out by filter from the polychromatic emission of an Hg or Xe lamp. In the case of the compound that is described in production example 1, light from an Nd:YAG laser of wavelength 540 nm is used for excitation to stimulate the test animal, and the fluorescence radiation at a wavelength of >580 nm is detected by an intensified CCD camera while obtaining whole-body-fluorescence images. In a parallel manner, the fluorescence is detected visually and photographically. Sections are prepared from the tumor material and studied by microscope (Zeiss Axiovert microscope with Cy3-filter set).

After injection of 1 μ mol/kg of the antibody-dye conjugate in F9-teratocarcinoma-carrying nude mice mentioned in the

production example, it was possible after four hours to detect an increased fluorescence signal in comparison to normal tissue based on whole-body-fluorescence images.

After preparation of the skin and the topmost tissue layers of the tumor, the fluorescence can be associated with the edge areas of the tumor. The microscopic evaluation of tumor sections produces an elevated fluorescence, which correlates with blood vessels of the tumor edge area.

Claims

1. Antibody-dye conjugates, characterized in that they preferably accumulate in the edge area of the cell tissue of a focus of disease and thus make the edge area of the focus of disease optically detectable.

2. Antibody-dye conjugates according to claim 1, of general formula I



in which

B stands for an antibody or an antibody fragment with high binding to EDB-fibronectin,


F stands for a dye from the class of coumarins, fluoresceins, carboxyfluoresceins, difluorofluoresceins, tetrabromofluoresceins, tetraiodofluoresceins, rhodamines, carboxyrhodamines, carboxyrhodols, 4,4-difluoro-4-bora-3a,4a-diaza-indacenes, polymethine dyes or tetrapyrrole dyes, or the terbium or europium complexes with DTPA or cyclene and its derivatives, and

n stands for 1 to 5.

3. Antibody-dye conjugates according to claims 1 and 2, wherein the dye is a cyanine dye, a merocyanine dye, an oxonol dye, a styryl dye or a squarilium dye.


4. Antibody-dye conjugates according to claims 1 to 3, wherein the dye is a cyanine dye such as carbocyanine, dicarbocyanine or tricarbocyanine.

5. Antibody-dye conjugates according to claims 1 to 4, wherein dye - (F)_n of general formula I is a cyanine dye of general formula II




in which

D stands for a radical III or IV



whereby the position labeled with a star means the interface site with radical B, and B can stand for group V, VI, VII, VIII or IX



in which

R^1 and R^2 mean C_1 - C_4 sulfoalkyl, a saturated or unsaturated, branched or linear C_1 - C_{50} alkyl chain, which optionally can be substituted with up to 15 oxygen atoms, and/or with up to 3 carbonyl groups, and/or with up to 5 hydroxy groups,

R^3 stands for group $-COOE^1$, $-CONE^1E^2$, $-NHCOE^1$, $-NHCONHE^1$, $-NE^1E^2$, $-OE^1$, $-OSO_3E^1$, $-SO_3E^1$, $-SO_2NHE^1$ or $-E^1$, whereby

E^1 and E^2 , independently of one another, stand for a hydrogen atom, C_1 - C_4 sulfoalkyl, saturated or unsaturated, branched or straight-chain C_1 - C_{50} alkyl, which optionally is interrupted with up to 15 oxygen atoms, and/or up to 3 carbonyl groups, and/or can be substituted with up to 5 hydroxy groups,

R^4 stands for a hydrogen atom or a fluorine, chlorine, bromine or iodine atom,

b stands for 2 or 3,

X stands for oxygen, sulfur or the group $=C(CH_3)_2$ or $-(CH=CH)-$, and

L stands for a direct bond or a linker, which is a straight-chain or branched carbon chain with up to 20 carbon atoms, which can be substituted with one or more $-OH$, $-COOH$, or SO_3 groups and/or optionally can be interrupted in one or more places by an $-O-$, $-S-$, $-CO-$, $-CS-$, $-CONH-$, $-NHCO-$, $-NHCSNH-$, $-SO_2-$, PO_4- or an $-NH$ group or an aryl ring.

6. Antibody-dye conjugates according to claims 1 to 5, wherein antibodies L19 and E8 are used as antibodies.

7. Antibody-dye conjugates according to claims 1 to 6, wherein the dye in the visible spectral range of the light induces an optical signal.

8. Antibody-dye conjugates according to claims 1 to 6, wherein the dye induces a fluorescence signal only with use of a defined wavelength range of the visible or near-infrared light.

9. Pharmaceutical agent comprising one or more antibody-dye conjugates according to claims 1 to 8 for intraoperative visualization of the edge areas of a focus of disease.

10. Pharmaceutical agent according to claim 9, in a mixture with suitable solvents, buffers and/or vehicles.

11. Use of the antibody-dye conjugates and agents according to claims 1 to 10 for intraoperative visualization of foci of disease.

12. Use of antibody-dye conjugates according to claims 1 to 10 for intraoperative visualization of the edge areas of a focus of disease.

13. Use of antibody-dye conjugates according to claims 1 to 10 for microscopic and macroscopic intraoperative visualization of the edge areas of a focus of disease.

14. Use of antibody-dye conjugates according to claims 1 to 8 for the production of an agent for surgical treatment of angiogenesis-dependent diseases, such as malignant tumors and metastases thereof, benign tumors, precancerous tissue changes, endometriosis, hemangiomas and ectopic pregnancies.

Abstract

Antibody-dye conjugates that are suitable to bind newly formed vessels to structures and their use for intraoperative visualization of pathological angiogenesis are described.

DECLARATION FOR PATENT APPLICATION

As ~~above~~ below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**ANTIBODY DYE CONJUGATES FOR BINDING TO TARGET STRUCTURES OF ANGIOGENESIS IN ORDER TO
INTRAOPERATIVELY DEPICT TUMOR PERIOHERIES**

the specification of which

is attached hereto

was filed on 08/19/00 as United States Application Number or PCT International Application Number PCT/EP00/08121 and (if applicable) was amended on _____

I hereby authorize our attorneys to insert the serial number assigned to this application.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 USC §119

APPLICATION NO.	COUNTRY	DAY/MONTH/YEAR FILED	PRIORITY CLAIMED
199 47 559.8	GERMANY	24/09/1999	YES

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

PROVISIONAL APPLICATION(S) UNDER 35 U.S.C. §119(e)

APPLICATION NUMBER	FILING DATE

I hereby claim the benefit under 35 U.S.C. §120 of any United States application, or §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. §112.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

PRIOR U.S./PCT INTERNATIONAL APPLICATION(S) DESIGNATED FOR BENEFIT UNDER 37 U.S.C. §120

APPLICATION NO.	FILING DATE	STATUS — PATENTED, PENDING, ABANDONED

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith: I. William Millen (19,544); John L. White (17,746); Anthony J. Zelano (27,969); Alan E.J. Branigan (20,565); John R. Moses (24,983); Harry B. Shubin (32,004); Brion P. Heaney (32,542); Richard J. Traverso (30,595); John A. Sopp (33,103); Richard M. Lebovitz (37,067); John H. Thomas (33,460); Catherine M. Joyce (40,668); Nancy J. Axelrod (44,014); James T. Moore (35,619); James E. Ruland (37,432); Jennifer J. Branigan (40,921) and Robert E. McCarthy (46,044)

Send Correspondence to Customer Number 23599



23599

PATENT TRADEMARK OFFICE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of sole or first inventor (given name, family name)	
Michael SCHIRNER	
Signature 	Date 06/06/02
Residence Berlin, GERMANY DEX	Citizenship GERMANY
Post Office Address Birkenallee 12, Berlin, Germany, D-13158	
Full Name of additional joint inventor (given name, family name)	
Kai LICHA	
Signature 	Date 07/06/02
Residence Falkensee, GERMANY DEX	Citizenship GERMANY
Post Office Address Bornimer Str. 17A, Falkensee, Germany, D-14612	
Full Name of additional joint inventor (given name, family name)	
Ludger DINKELBORG	
Signature 	Date 07/06/02
Residence Berlin, GERMANY DEX	Citizenship GERMANY
Post Office Address Ortwinstr. 7, Berlin, Germany, D-13456	
Full Name of additional joint inventor (given name, family name)	
Signature	Date
Residence	Citizenship
Post Office Address	
Full Name of additional joint inventor (given name, family name)	
Signature	Date
Residence	Citizenship
Post Office Address	

Additional joint inventors are named on separately numbered sheets attached hereto.